Phase 1 Moderate Hepatic Impairment Clinical Trials

3 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–3 of 3 trials

Recruiting

Phase 1

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Moderate Hepatic Impairment

AstraZeneca20 enrolled2 locationsNCT07343960

Recruiting

Phase 1

A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment

Taisho Pharmaceutical Co., Ltd.24 enrolled1 locationNCT07231029

Recruiting

Phase 1

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Moderate Hepatic ImpairmentHepatic Impairment

Exelixis20 enrolled2 locationsNCT06962332